8-K: Aligos Advances HBV Drug to Phase 2, Reports Q2 Loss

Aligos Therapeutics announced significant progress in its lead chronic hepatitis B program, ALG-000184, entering Phase 2, alongside reporting a net loss of $15.9 million for the second quarter of 2025.

Summary

• Aligos Therapeutics reported recent business progress and financial results for the second quarter ended June 30, 2025.
• The Phase 2 B-SUPREME study of ALG-000184 for chronic hepatitis B virus (HBV) infection is well underway, with regulatory approvals obtained in multiple countries, site activations in progress, and dosing expected to commence in the coming weeks.
• Phase 1 data for ALG-000184, presented at EASL 2025, showed that 96 weeks of treatment was well tolerated, exhibited a favorable pharmacokinetic profile, and suggested potentially best-in-class antiviral activity, with 100% of HBeAg+ subjects (9 of 9) achieving HBV DNA < LLOQ at Week 96 and 100% of HBeAgsubjects (8 of 8) achieving HBV DNA < LLOQ (TND) at Week 96.
• The Phase 2a HERALD data for ALG-055009, a potential best-in-class THR-agonist for metabolic dysfunction-associated steatohepatitis (MASH), demonstrated statistically significant reductions in liver fat at week 12 and significant improvements in atherogenic lipids.
• Cash, cash equivalents, and investments totaled $122.9 million as of June 30, 2025, compared with $56.9 million as of December 31, 2024, with sufficient funding expected into the second half of 2026.
• The net loss for the three months ended June 30, 2025, was $15.9 million, or $(1.53) per common share, compared to a net income of $5.1 million, or $0.81 per common share, for the same period in 2024.
• Research and development (R&D) expenses decreased to $14.0 million in Q2 2025 from $21.1 million in Q2 2024, primarily due to the completion of the MASH Phase 2a clinical trial, partially offset by increased spend in the chronic HBV infection program.
• General and administrative (G&A) expenses decreased to $5.6 million in Q2 2025 from $6.4 million in Q2 2024, mainly due to lower third-party expenses, including legal fees.
• The change in fair value of 2023 common warrants resulted in income of $1.7 million in Q2 2025, a significant decrease from $30.4 million in Q2 2024, which was the primary driver of the swing to a net loss.

Sentiment

Score: 7

Explanation: The filing presents strong positive clinical progress for its lead assets and a significantly improved cash position with an extended runway. While a net loss was reported, it was primarily due to a non-operational accounting item rather than core operational deterioration. The need for external funding for some pipeline assets introduces a degree of future uncertainty.

Positives

• Initiation of the Phase 2 B-SUPREME study for ALG-000184 (HBV) is well underway with regulatory approvals in multiple countries and dosing expected to commence soon.
• Phase 1 data for ALG-000184 demonstrated strong antiviral activity, with 100% of subjects achieving HBV DNA < LLOQ at Week 96 in both HBeAg+ and HBeAgcohorts, suggesting potential best-in-class efficacy.
• ALG-000184 was well tolerated in Phase 1, with no viral breakthrough or known CAM resistant mutations observed.
• ALG-055009 (MASH) met its primary endpoint in Phase 2a, showing statistically significant reductions in liver fat and improvements in atherogenic lipids, with a favorable tolerability profile.
• Cash, cash equivalents, and investments increased significantly to $122.9 million as of June 30, 2025, from $56.9 million as of December 31, 2024.
• The company expects its current cash, cash equivalents, and investments to provide sufficient funding for planned operations into the second half of 2026.
• Research and development (R&D) expenses decreased by $7.1 million year-over-year, reflecting efficient resource allocation following the completion of the MASH Phase 2a trial.

Negatives

• The company reported a net loss of $15.9 million for the second quarter of 2025, a significant decline from a net income of $5.1 million in the same period of 2024.
• The primary driver of the net loss was a substantial decrease in income from the change in fair value of 2023 common warrants, which fell from $30.4 million in Q2 2024 to $1.7 million in Q2 2025.

Risks

• Risks and uncertainties inherent in the drug development process, including the clinical-stage of development.
• Challenges associated with designing and conducting clinical trials.
• Uncertainties related to regulatory approval processes and the timing of regulatory filings.
• Difficulties in manufacturing drug products.
• Ability to successfully establish, protect, and defend intellectual property.
• Sufficiency of capital resources to fund operations.
• Reliance on third parties for manufacturing and development efforts.
• Changes in the competitive landscape.
• Impact of global events and other macroeconomic conditions on the business.

Future Outlook

The company anticipates dosing to commence for the Phase 2 B-SUPREME study of ALG-000184 in the coming weeks, with interim data expected in 2026 and topline data in 2027. Data readouts from the Phase 1 study of ALG-000184, including post-treatment data, are planned for scientific conferences this year. The company is continuing to evaluate a variety of options to fund continued development of ALG-055009, including potential out-licensing. Future development of ALG-097558 is expected to be funded by external sources. Current cash, cash equivalents, and investments are projected to provide sufficient funding for planned operations into the second half of 2026.

Management Comments

• "Initiation of the Phase 2 B-SUPREME study of ALG-000184 is well underway with regulatory approvals across a number of countries, including the US, China, Canada, Taiwan, UK, New Zealand, and Moldova," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics.
• "Site activations are in progress, subjects are being screened, and we expect dosing to commence in the coming weeks."
• "This pertinent study is the next step in our journey to potentially deliver better therapies for patients living with HBV infection and create value for our stakeholders."
• "The Phase 1 data showcasing 96 weeks of treatment presented at the EASL meeting suggests that ALG-000184 has the potential to replace standard of care treatment for chronic suppression of HBV infection and may become the backbone of treatments aimed at a functional cure."
• "We remain excited about the potential of ALG-000184 and the entirety of our pipeline, including ALG-055009 which remains in discussions with potential partners."

Industry Context

Aligos Therapeutics operates in the clinical-stage biotechnology sector, focusing on liver and viral diseases, including chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. The company aims to develop 'best-in-class' therapies, positioning itself to address high unmet medical needs in these areas. The advancement of ALG-000184 into Phase 2 for HBV, a disease with a large global patient population and significant need for improved treatments, aligns with broader industry efforts to find functional cures. Similarly, the positive Phase 2a data for ALG-055009 in MASH, a rapidly growing liver disease, positions Aligos within a competitive but high-potential therapeutic area, especially with its demonstrated cardiovascular benefits.

Comparison to Industry Standards

• The Phase 2 B-SUPREME study of ALG-000184 is designed as an active-controlled study comparing ALG-000184 monotherapy with tenofovir disoproxil fumarate, a widely used standard of care treatment for chronic HBV infection, aiming to demonstrate competitive or superior efficacy and safety.
• ALG-000184's Phase 1 data, showing 100% HBV DNA suppression at Week 96 in both HBeAg+ and HBeAgsubjects, suggests a potentially best-in-class antiviral activity compared to existing therapies.
• ALG-055009 demonstrated statistically significant improvements in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B, even in the context of stable GLP-1 agonist or statin use, indicating a potential added benefit for patients already on these common treatments for metabolic and cardiovascular conditions, which is a key differentiator in the MASH landscape.

Stakeholder Impact

• Shareholders: Potential for increased value from significant clinical pipeline advancements and an extended cash runway, balanced by a reported net loss primarily due to non-operational factors and future funding needs for certain programs.
• Patients: Potential for improved and 'best-in-class' therapies for chronic HBV infection, MASH, and coronaviruses, addressing high unmet medical needs.
• Employees: Continued engagement in research and development activities for promising drug candidates.
• Creditors: Improved financial liquidity with a substantial increase in cash and investments, enhancing the company's ability to meet its obligations.

Next Steps

• Dosing commencement for the Phase 2 B-SUPREME study of ALG-000184 in the coming weeks.
• Data readouts, including post-treatment data, from the ALG-000184 Phase 1 study planned for scientific conferences this year.
• Interim data from the ALG-000184 Phase 2 B-SUPREME study expected in 2026.
• Topline data from the ALG-000184 Phase 2 B-SUPREME study expected in 2027.
• Continuing to evaluate options to fund continued development of ALG-055009, including potential out-licensing.
• Future development of ALG-097558 is expected to be funded by external sources.

Key Dates

Recommendation

The company demonstrates strong clinical progress with its lead HBV asset, ALG-000184, advancing to Phase 2 with promising Phase 1 data suggesting best-in-class potential. The extended cash runway into the second half of 2026 provides financial stability for ongoing operations. However, the significant swing to a net loss in Q2 2025, primarily due to a non-operational decrease in warrant fair value income, introduces a degree of financial volatility. While the pipeline shows promise, the stated need for external funding for ALG-055009 and ALG-097558 indicates potential future dilution or reliance on partnerships. Given the positive clinical momentum balanced by the financial shift and future funding needs, a "hold" recommendation is appropriate for investors to monitor further clinical milestones and financial developments.

Keywords

Aligos Therapeutics, ALGS, biotechnology, liver disease, viral disease, HBV, hepatitis B, MASH, NASH, metabolic dysfunction-associated steatohepatitis, coronavirus, drug development, clinical trials, Phase 2, Phase 1, financial results, Q2 2025, ALG-000184, ALG-055009, ALG-097558